Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera ® (olanzapine pamoate monohydrate)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
ZypAdhera® (olanzapine pamoate): Use in Patients Following a Vegetarian or Vegan Diet
ZypAdhera (including the solvent) does not contain ingredients sourced from animals or animal products including blood, dairy and eggs.
Label Information
The active ingredient of ZypAdhera is olanzapine pamoate.1
The excipients of ZypAdhera are:1
Powder:
- None
Solvent
- Carmellose sodium
- Mannitol
- Polysorbate 80
- Water for injections
- Hydrochloric acid (for pH adjustment)
- Sodium hydroxide (for pH adjustment)
References
1ZypAdhera [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: 11 April 2023